Robert I.  Blum net worth and biography

Robert Blum Biography and Net Worth

CEO of Cytokinetics

Robert has served as our President and Chief Executive Officer of Cytokinetics and a member of our Board of Directors since 2007. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998.

Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981.

Robert serves as the Chairman of the Board of Directors of Gamida Cell (NASDAQ:GMDA). Robert previously served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry.

He serves on the Boards of Jewish Family & Children’s Services and Temple Emanu-el in San Francisco. He is also a founding member of the Board of Life Science Cares Bay Area, a non profit organization established to support relief efforts for education, homelessness and food & healthcare insecurity in the Bay Area. Previously, he served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League.

Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums.

Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.

Robert was a fan of mountain bluegrass music long before it was considered fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget on long hikes in the Presidio.

What is Robert I. Blum's net worth?

The estimated net worth of Robert I. Blum is at least $30.04 million as of January 31st, 2024. Mr. Blum owns 441,797 shares of Cytokinetics stock worth more than $30,042,196 as of April 15th. This net worth evaluation does not reflect any other investments that Mr. Blum may own. Additionally, Mr. Blum receives a salary of $1,140,000.00 as CEO at Cytokinetics. Learn More about Robert I. Blum's net worth.

How old is Robert I. Blum?

Mr. Blum is currently 60 years old. There are 4 older executives and no younger executives at Cytokinetics. Learn More on Robert I. Blum's age.

What is Robert I. Blum's salary?

As the CEO of Cytokinetics, Incorporated, Mr. Blum earns $1,140,000.00 per year. Learn More on Robert I. Blum's salary.

How do I contact Robert I. Blum?

The corporate mailing address for Mr. Blum and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Robert I. Blum's contact information.

Has Robert I. Blum been buying or selling shares of Cytokinetics?

Robert I. Blum has not been actively trading shares of Cytokinetics within the last three months. Learn More on Robert I. Blum's trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (CEO), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 34 times. They sold a total of 379,465 shares worth more than $20,438,114.45. The most recent insider tranaction occured on April, 9th when EVP Fady Ibraham Malik sold 32,605 shares worth more than $2,422,877.55. Insiders at Cytokinetics own 3.8% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 4/9/2024.

Robert I. Blum Insider Trading History at Cytokinetics

See Full Table

Robert I. Blum Buying and Selling Activity at Cytokinetics

This chart shows Robert I. Blum's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $68.00
Low: $67.45
High: $71.60

50 Day Range

MA: $71.93
Low: $63.75
High: $80.99

2 Week Range

Now: $68.00
Low: $25.98
High: $110.25

Volume

1,516,923 shs

Average Volume

1,384,179 shs

Market Capitalization

$7.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68